Trypsin 48 mg + Bromelain 90 mg + Rutoside Trihydrate 100 mg + Diclofenac Sodium 50 mg Enteric-Coated Tablet

Trypsin 48 mg + Bromelain 90 mg + Rutoside Trihydrate 100 mg + Diclofenac Sodium 50 mg Enteric-Coated Tablet is a enteric-coated tablet formulated with Trypsin 48 mg + Bromelain 90 mg + Rutoside Trihydrate 100 mg + Diclofenac Sodium 50 mg. The active ingredient profile is Trypsin; Bromelain; Rutoside Trihydrate; Diclofenac Sodium, placing the product in the proteolytic enzyme + nsaid combination category. The formulation combines analgesic/anti-inflammatory ingredients with proteolytic enzyme components commonly used as adjuncts in clinician-managed inflammatory or soft-tissue conditions. The enteric coating is intended to delay tablet disintegration until after passage through the stomach, subject to the approved finished-product specification. For website cataloguing, composition, strength, dosage form and release/coating characteristics should be displayed prominently and consistently. The description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and the prescriber’s judgement. Prescription status, precautions, interactions, adverse effects and dosing must be checked against the current approved product label before publication. Manufacturer, licence, storage, shelf-life, pack configuration and market-specific regulatory details should be added only from verified product documentation.